Biotech Archives - Page 129 of 795

2 minute read

Oxford University Kicks off Human Study for AstraZeneca’s COVID-19 Vaccine Technology in Nipah Virus Defense

January 11, 10:33 AM

Join the fight against Nipah virus! Oxford Vaccine Group launches groundbreaking ChAdOx1 NipahB vaccine trial, targeting the deadly virus. 51 participants aged 18-55. Funded by CEPI. Help combat Nipah and be part of a vital initiative.

AZN

2 minute read

FDA Allows Importing Unapproved But Essential Syphilis Treatment Amid Shortage Of Pfizer’s Antibiotic

By Vandana Singh

January 11, 10:24 AM

FDA collaborates with Laboratoires Delbert to address syphilis treatment shortage. Learn about the temporary import of Extencilline, an alternative to Bicillin. Shortage expected until June.

PFE

5 minute read

“Amazon’s Just Walk Out Technology Rolls Out To Hospitals, With ‘Badge Pay’ For Doctors, Nurses, And Health Care Staff”

By Benzinga Newsdesk

January 11, 10:11 AM

https://www.aboutamazon.com/news/retail/amazon-just-walk-out-technology-badge-payBadge pay is the latest Just Walk Out technology innovation that removes friction for retailers while providing convenience for

AMZN

1 minute read

Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

By Benzinga Newsdesk

January 11, 9:43 AM

Lexaria Bioscience Corp. (NASDAQ:LEXX) announces the availability of a broadcast titled, "Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs."To hear the AudioPressRelease, please visit: The

LEXX

2 minute read

Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition

By Vandana Singh

January 11, 9:31 AM

AbbVie Inc's (NYSE: ABBV) unwavering confidence in Botox's resilience within the aesthetics market with a commanding 68% market share remains steadfast. Despite a recent FDA petition addressing potential risks, AbbVie emphasizes its commitment to safety with existing 'black box' warnings. Amidst economic uncertainties and emerging competitors, AbbVie anticipates continued strength.

ABBV

2 minute read

Mainz Biomed And TestDNA Drive CRC Innovation At The 10th Gdańsk Gastroenterology Symposium On January 12th–13th, 2024 To Discuss Colorectal Cancer – The Need For Earlier Detection

By Benzinga Newsdesk

January 11, 9:05 AM

https://www.eqs-news.com/news/corporate/mainz-biomed-and-testdna-drive-crc-innovation-at-the-10th-gdansk-gastroenterology-symposium/1975437Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology

MYNZ

9 minute read

30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond

By Lara Goldstein

January 10, 8:56 PM

The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health conditions, this sector has attracted growing attention and investment.

CYBN

1 minute read

Analyst Highlights Aclaris Therapeutics’ Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations

By Vandana Singh

January 10, 4:12 PM

Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to

ACRS

2 minute read

Company Exploring CBG Production Signals New Era Of Commercial Success In Synthetic Biology

By Jelena Martinovic

January 10, 3:38 PM

Biotechnology company Willow Biosciences generated around $1.3m in revenues in 2023, a 60% increase from the previous year. The company has hailed 2023 as a "transformative year," citing the launch of its BioOxi bio-oxidation platform technology as one of its top achievements. The AI-driven selective hydroxylation platform removes multiple chemical steps and reduces the cost of manufacturing target molecules. The technology has enabled Willow to accelerate its path to nearer-term and potentially larger revenue opportunities while reducing operational expenses. The company also engaged in multiple partnerships with innovators and generic pharmaceutical companies, resulting in portfolio expansion and diversification. Willow underwent a restructuring of its corporate and operational framework, including consolidating operations in the San Francisco Bay area and making changes to its leadership team. In 2024, Willow plans to capitalize on the BioOxi technology platform to bring its corticosteroids program to commercial readiness and identify strategic partners for pipeline expansion and acceleration.

CANSF

2 minute read

Analyst Assesses Cell-Programming Focused Ginkgo Bioworks’ Positioning Amid Revenue Surge, Program Adjustments

By Vandana Singh

January 10, 3:29 PM

Wednesday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million.

BIIB